

# Pathophysiology of the respiratory system I

Structural properties of airways and lungs


Respiration: ventilation & diffusion & perfusion

Pulmonary mechanics and common ventilation abnormalities

Airflow resistance and dynamic collapse

Obstructive diseases (COPD and bronchial asthma)





**Figure 17.1** Diagrammatic view of human respiratory system (Sectional view of the left lung is also shown)




**STRUCTURAL-FUNCTIONAL CONSIDERATIONS IMPORTANT  
FOR PP OF RESPIRATION & PARTICULAR DISORDERS**

# The delicate structure-function coupling of lungs

- The main role of the respiratory system is to **extract oxygen from the external environment** and **dispose of** waste gases, principally **carbon dioxide**
  - at the end of deep breath 80% of lung volume is air, 10% blood and 10% tissue
    - lung tissue spreads over an enormous area !
- The lungs have to provide
  - a **large surface area** accessible to the environment (~tennis court area) for gas exchange
  - alveoli walls have to present **minimal resistance to gas diffusion**
- Close contact with the external environment means lungs can be damaged by dusts, gases and infective agents
  - **host defense** is therefore a key priority for the lung and is achieved by a combination of structural and immunological means



# Structure of airways




- There are about 23 (18-30) divisions ( $2^{23}$  i.e. approx. 8 millions of sacs) between the trachea and the alveoli
  - the first seven divisions, the bronchi have:
    - walls consisting of cartilage and smooth muscle
    - epithelial lining with cilia and goblet cells
    - submucosal mucus-secreting glands
    - endocrine cells - Kulchitsky or APUD (amine precursor and uptake decarboxylation) containing 5-hydroxytryptamine
  - the next 16-18 divisions the bronchioles have:
    - no cartilage
    - muscular layer progressively becomes thinner
    - a single layer of ciliated cells but very few goblet cells
    - granulated Clara cells that produce a surfactant-like substance

Source: McPhee SJ, Ganong WF: *Pathophysiology of Disease: An Introduction to Clinical Medicine*, 5th Edition: <http://www.accessmedicine.com>



Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

# Wall structure of conducting airways and respiratory region




# Alveoli

- There are approximately 300-400 million alveoli in each lung with the total surface area is 40-80m<sup>2</sup>
- Cell types of the epithelial lining
  - **type I pneumocytes**
    - an extremely thin cytoplasm, and thus provide only a thin barrier to gas exchange, derived from type II pneumocytes
    - connected to each other by tight junctions that limit the fluid movements in and out of the alveoli
    - easily damageable, but cannot divide!
  - **type II pneumocytes**
    - slightly more numerous than type I cells but cover less of the epithelial lining
    - the source of type I cells and surfactant
  - **macrophages**




# Alveolo - capillary barrier



- Alveolar epithelia
  - type I
  - type II
- Capillary endothelium
  - non-fenestrated
- Interstitium
  - cells (very few!)
    - fibroblasts
    - contractile cells
    - immune cells (interstitial macrophages, mast cells, ...)
  - ECM
    - elastin and collagen fibrils





# Lung defense – multiple mechanisms (details later)



# Respiration and gas exchange in the lungs


- **ventilation** = mechanical process
  - breathing in narrower meaning
- **diffusion** = chemical process
  - through alveolo-cappillary barrier
- **perfusion** = circulatory process
  - circulation of blood in lungs






# ABNORMALITIES OF VENTILATION & PULMONARY MECHANICS

# Mechanics of ventilation – breathing cycle



- pressures and pressure gradients
  - pressure on the body surface ( $P_{bs}$ ),
    - usually equal to atmospheric ( $P_{ao}$ )
  - alveolar pressure ( $P_{alv}$ )
  - „elastic“ pressure ( $P_eI$ )
    - generated by lung parenchyma and surface tension
  - pressure in pleural cavity ( $P_{pl}$ )
  - trans-pulmonary pressure ( $P_L$ )
    - pressure difference between alveolus and pleural cavity
    - $P_L = P_{alv} - P_{pl}$
  - trans-thoracic pressure ( $P_{rs}$ )
    - pressure difference between alveolus and body surface
    - determines actual phase of ventilation, i.e. inspirium or expirium
    - $P_{rs} = P_{alv} - P_{bs}$

# Ventilation (breathing) as a mechanical process



Copyright © 2001 Benjamin Cummings, an imprint of Addison Wesley Longman, Inc.



- **Inspiration**

- an active process that results from the descent of the **diaphragm** and movement of the ribs upwards and outwards under the influence of the **intercostal muscles**
  - in resting healthy individuals, contraction of the diaphragm is responsible for most inspiration
- respiratory muscles are similar to other skeletal muscles but are less prone to fatigue
  - weakness may play a part in respiratory failure resulting from neurological and muscle disorders and possibly with severe chronic airflow limitation
- inspiration against increased resistance may require the use of the accessory muscles of ventilation
  - sternocleidomastoid and scalene muscles


- **Expiration**

- follows passively as a result of gradual lessening of contraction of the intercostal muscles, allowing the lungs to collapse under the influence of their own elastic forces (**elastic recoil**)
- forced expiration is also accomplished with the aid of accessory muscles
  - abdominal wall


# Muscles performing inspiration



© ABPI 2013



# Ventilation




1. Barometric air pressure ( $P_B$ ) is equal to alveolar pressure ( $P_{alv}$ ) and there is no air movement.

2. Increased thoracic volume results in increased alveolar volume and decreased alveolar pressure. Barometric air pressure is greater than alveolar pressure, and air moves into the lungs.

- pressure necessary to distend lungs has to overcome two kinds of resistances
  - **(1) STATIC = elastic recoil**
    - in the respiratory part of airways and lung parenchyma
  - **(2) DYNAMIC = airway resistance**
    - in the convection part of airways
- energy requirements for respiratory muscles to overcome these resistances are normally quite low
  - 2-5 % of a total  $O_2$  consumption
- but increases dramatically when resistance increases (up to 30%)


# Dyspnea (breathlessness)

- on physical exertion is normal and not considered a symptom unless the level of exertion is very light, such as when walking slowly
- although breathlessness is a very common symptom, the sensory and neural mechanisms underlying it remain obscure
- the sensation of breathlessness is derived from at least three sources:
  - changes in lung volume
    - sensed by receptors in thoracic wall muscles signalling changes in their length
  - the tension developed by contracting muscles
    - this can be sensed by Golgi tendon organs
    - tension developed in normal muscle can be differentiated from that developed in muscles weakened by fatigue or disease
  - central perception of the breathing effort





common causes of dyspnea






# (ad 1) Elastic properties of the lung




- lungs have an inherent elastic property that causes them to tend to collapse generating a negative pressure within the pleural space
  - the strength of this retractive force relates to the volume of the lung
    - for example, at higher lung volumes the lung is stretched more, and a greater negative intrapleural pressure is generated
  - at the end of a quiet expiration, the retractive force exerted by the lungs is balanced by the tendency of the thoracic wall to spring outwards
    - at this point, respiratory muscles are resting and the volume of the lung is known as the **functional residual capacity (FRC)**






# Elastic recoil is determined by two kinds of forces

- **lung compliance** (“distensibility”)
  - a measure of the relationship between this retractive force and lung volume (pressure-volume relationship)
  - defined as the change in lung volume brought about by unit change in transpulmonary (intrapleural) pressure (L/kPa)
- **surface tension** produced by the layer of fluid that lines the alveoli
  - determined by the cohesive (binding together) forces between molecules of the same type
    - on the inner surface of the alveoli there is a fluid that can resist lung expansion
    - there would be a lot of surface tension because there is an air-water interface in every alveolus
    - if surface tension remained constant, decreasing  $r$  during expiration would increase  $P$  and smaller alveolus would empty into large one
  - this collapsing tendency is offset by **pulmonary surfactant** which significantly lowers surface tension




# Pulmonary surfactant

- Complex mixture of lipids and proteins at the alveolar cell surface (liquid – gas interface) reducing surface tension
  - superficial layer made of phospholipids (dipalmitoyl lecithin)
  - deeper layer (hypophase) made of proteins (SP-A, -B, -C, -D)
- Surfactant maintains lung volume at the end of expiration
- Continually recycles
  - influenced by many hormones incl. glucocorticoids
    - lung maturation in pre-term newborns





Pulmonary surfactant adsorption to the interface and surface film formation Processes that may contribute to transport of surface active surfactant species to the interface include 1) direct cooperative transfer of surfactant from secreted lamellar body-like particles touching the interface, 2) unravelling of secreted lamellar bodies to form intermediate structures such as tubular myelin (TM) or large surfactant layers that have the potential to move and transfer large amounts of material to the interface, and 3) rapid movement of surface active species through a continuous network of surfactant membranes, a so-called surface phase, connecting secreting cells with the interface.




# Abnormalities of elastic properties

- change of lung compliance (TLC, FRC, RV)
  - ↑ pulmonary **emphysema**, aging (↑ TLC, ↑ FRC, ↑ RV)
  - ↓ **interstitial disease** (↓TLC, ↓ FRC, ↓ RV), e.g. pulmonary fibrosis or bronchopneumonia
- lack of surfactant (↓TLC, ↓ FRC, ↓ RV)
  - infant or adult **respiratory distress syndromes** (IRDS or ARDS, resp.), i.e. lung collapse
  - alveolar lung **edema** (damages surfactant)
- diseases that affect the movement of the thoracic cage and diaphragm
  - marked obesity
  - diseases of the thoracic spine
    - ankylosing spondylitis and kyphoscoliosis
  - neuropathies
    - e.g. the Guillain-Barré syndrome)
  - injury to the phrenic nerves
  - myasthenia gravis



# (ad 2) Airway (dynamic) resistance

- Poiseuille's law for pressure states that pressure is
  - directly proportional to flow, tube length, and viscosity
  - and it is inversely proportional to tube radius
- Overcoming increased resistance requires **forced expiration**




Q	Flow rate
P	Pressure
r	Radius
$\eta$	Fluid viscosity
l	Length of tubing



$$Q = \frac{\pi P r^4}{8 \eta l}$$



# Airflow – where is the highest resistance?





$$R = \frac{8\eta l}{\pi r^4}$$




# Airflow

- From the trachea to the periphery, the airways become smaller in size (although greater in number)
  - **the cross-sectional area available for airflow increases as the total number of airways increases**
  - the flow of air is greatest in the trachea and slows progressively towards the periphery (as the velocity of airflow depends on the ratio of flow to cross-sectional area)
    - in the terminal airways, gas flow occurs solely by diffusion
- The **resistance to airflow** is very low (0.1-0.2 kPa/L in a normal tracheobronchial tree), **steadily increasing from the small to the large airways**
- Airway tone is under the control of the autonomic nervous system
  - bronchomotor tone is maintained by **vagal efferent nerves**
  - many **adrenoceptors** on the surface of bronchial muscles respond **to circulating catecholamines**
    - sympathetic nerves do not directly innervate them!
- Airway resistance is also **related to lung volumes**
  - because airways are 'tethered' by alveoli (i.e. pulled open by radial traction)
  - visible on bronchoscopy
  - patients with obstruction benefit from breathing in high lung volumes



# Airflow resistance – effect of changed airway diameter


$$R = \frac{8\eta l}{\pi r^4}$$



- theoretical amplifying effect of luminal mucus on airflow resistance in asthma
  - (a) According to Poiseuille's law, resistance to flow ( $R$ ) is proportional to the reciprocal of the radius ( $r$ ) raised to the fourth power.
  - (b) Without luminal mucus, bronchoconstriction to reduce the airway radius by half increases airflow resistance 16-fold.
  - (c) A small increase in mucus thickness ( $t_M$ ), which reduces the radius of the airway by only one-tenth, has a negligible effect on airflow in the unstricted airway (compare with panel a).
  - (d) With bronchoconstriction, the same amount of luminal mucus markedly amplifies the airflow resistance of this airway

# Airflow pattern



- Movement of air through the airways results from a **difference between the pressure in the alveoli and the atmospheric pressure**
  - alveolar pressure ( $P_{ALV}$ ) is equal to the elastic recoil pressure ( $P_{EL}$ ) of the lung plus the pleural pressure ( $P_{PL}$ )
  - positive  $P_{ALV}$  occurs in expiration and a negative pressure occurs in inspiration
- During quiet breathing the sub-atmospheric pleural pressure throughout the breathing cycle slightly distends the airways
  - during vigorous expiratory efforts (e.g. cough) the central airways are compressed by positive pleural pressures exceeding 10 kPa
  - the airways do not close completely because the driving pressure for expiratory flow (alveolar pressure) is also increased
- When there is no airflow (i.e. during a pause in breathing) the tendency of the lungs to collapse (the positive  $P_{EL}$ ) is exactly balanced by an equivalent negative  $P_{PL}$




*The relationship between maximal flow rates on expiration and inspiration is demonstrated by the maximal flow-volume (MFV) loops*

# Dynamic compression

- In forced expiration, the driving pressure raises both the  $P_{ALV}$  and the  $P_{PL}$ 
  - between the alveolus and the mouth, a point will occur (C) where the airway pressure will equal the intrapleural pressure, and airway compression will occur
    - equal pressure point**
  - however, this compression of the airway is temporary, as the transient occlusion of the airway results in an increase in pressure behind it (i.e. upstream) and this raises the intra-airway pressure so that the airways open and flow is restored
    - the airways thus tend to vibrate at this point of 'dynamic compression'



# Dynamic Airway Collapse




Expiratory effort --- Increased kinetic energy --- Reduced lateral pressure --- Dynamic Airway Collapse


Fig. 13-5

KMc

# Dynamic compression in various situations




- The respiratory system is represented as a piston with a single alveolus and the collapsible part of the airways within the piston
  - C, compression point;  $P_{ALV}$ , alveolar pressure;  $P_{EL}$ , elastic recoil pressure;  $P_{PL}$ , pleural pressure.
  - (a) at rest at functional residual capacity
  - (b) forced expiration in normal subjects
  - (c) forced expiration in a patient with COPD



## MOST COMMON OBSTRUCTION DISEASES



# Mechanisms of airway obstruction





- Narrowing of the airway lumen may be due to:
  - a) mucus, cells or other material within the lumen
  - b) thickening of the airway wall that encroaches on the lumen (hypertrophy)
  - c) shortening of smooth muscle around the lumen (bronchoconstriction)
  - d) collapse of the airway wall into the lumen (emphysema)

# Ventilation disorders due to bronchial obstruction – basic pathophysiological characteristics


- obstruction in airways massively increases their **resistance** (dynamic resistance)
  - Hagen-Poiseuille law
- since inspiration is an active process (muscles and negative alv. and transthoracic pressure overcome resistances) but expiration passive one, obstruction leads to an **impairment of expiration**
- participation of auxiliary respiratory muscles leads to
  - dynamic compression, air trapping and **hyperinflation of the lungs**
    - $\uparrow$  residual volume (FRC, RV, TLC)
  - $\uparrow$  breathing effort and thus **dyspnea**
- $\downarrow$  dynamic ventilatory parameters (spirometry)
  - more time needed to exhale FVC ( $\downarrow$  FEV1)

$$R = \frac{8nl}{\pi r^4}$$




# Airflow obstruction

- In patients with severe COPD, limitation of expiratory flow occurs even during tidal breathing at rest
- To increase ventilation these patients have to breathe at higher lung volumes and also allow more time for expiration by increasing flow rates during inspiration, where there is relatively less flow limitation
- Thus patients with severe airflow limitation have a prolonged expiratory phase to their respiration




# Lung Volumes and Capacities




set by opposing recoil forces of the chest and lungs and the effort of respiratory muscles

# Ventilation disorders due to bronchial obstruction – basic pathophysiological characteristics




shift towards inspiration reserve volume with greater static resistances of airways (increased breathing effort)




# Chronic obstructive pulmonary disease (COPD)

- COPD is not solely **pulmonary** disease but **systemically** manifested syndrome
- definition of pulmonary component of COPD:
  - permanent bronchial obstruction, not fully reversible, usually progressive, characterized by abnormal inflammatory response to environmental harmful stimuli
  - bronchial obstruction in COPD is caused by individually variable combination of:
    - **chronic bronchitis** (with excessive resp. secretion)
    - **pulmonary emphysema** (i.e. destruction of lung parenchyma)
    - **obstructive bronchiolitis** (with obstruction of small airways)
- systemic component comprises:
  - changes in pulmonary vasculature
  - hypoxic hypoxia



Chronic Obstructive Pulmonary Disease (COPD)



# COPD

CHRONIC AIRFLOW LIMITATION  
"EMPHYSEMA AND CHRONIC BRONCHITIS"

- Easily Fatigued
- Frequent Respiratory Infections
- Use of Accessory Muscles to Breathe
- Orthopneic



- Wheezing
- Pursed-Lip Breathing
- Chronic Cough
- Barrel Chest
- Dyspnea
- Prolonged Expiratory Time

- Bronchitis - Increased Sputum

- Cor Pulmonale (Late in Disease)

- Thin in Appearance

- Digital Clubbing

©2007 Nursing Education Consultants, Inc.

## Stage I: Mild

Spirometry shows mild airflow limitation ( $FEV_1 \geq 80\%$  predicted;  $FEV_1/FVC < 0.70$ ). Primary symptoms are chronic cough and sputum production

## Stage II: Moderate

Spirometry shows a worsening airflow limitation ( $FEV_1 \geq 50\%$  and  $< 80\%$  predicted;  $FEV_1/FVC < 0.70$ ). Patients often experience dyspnea, which may interfere with their daily activities.

## Stage III: Severe

Spirometry shows severe airflow limitation ( $FEV_1 \geq 30\%$  and  $< 50\%$  predicted;  $FEV_1/FVC < 0.70$ ). Symptoms of cough and sputum production typically continue, dyspnea worsens, and repeated exacerbations occur.



## Stage IV: Very Severe

Spirometry shows very severe airflow limitation ( $FEV_1 < 30\%$  predicted or  $FEV_1 < 50\%$  predicted;  $FEV_1/FVC < 0.70$  plus chronic respiratory failure). Complications such as respiratory failure or heart failure may develop.

1. Rodriguez-Roisin R, Anzueto A, Bourbeau J, et al; GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2009). Global Initiative for Chronic Obstructive Lung Disease Web site: <http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003>. Accessed March 8, 2010.

# COPD


- COPD is one of the most frequent chronic illnesses and one of the commonest causes of mortality worldwide
  - 4th place leading cause of death in countries with high prevalence of smoking
    - after MI, tumors and stroke
- **85-90% of COPD patients are smokers**
  - Incidence is increased up to twentyfold in smokers compared to non-smokers
  - even more so in workers exposed to air pollution







# Chronic bronchitis ( $\varnothing > 2\text{mm}$ ) and bronchiolitis ( $\varnothing < 2\text{mm}$ )

- symptomatic definition
  - hypersecretion of mucus and chronic productive cough that continues for at least 3 months of years for at least 2 consecutive years
- however patients typically suffer from chronic bronchitis without obstruction for a long time and only then develop bronchial obstruction (i.e. COPD)
  - there are of course patients with COPD without clinical signs of chronic bronchitis
  - some chronic bronchitis cases never progress to COPD
- in manifest COPD presence of chronic bronchiolitis is obligatory dominantly responsible (together with pulmonary emphysema) for obstruction
  - chronic persistent inflammation of small airways ( $\varnothing \leq 2\text{ mm}$ )
  - the ratio between chronic bronchiolitis and pulmonary emphysema is entirely individual




# Chronic bronchitis – pathological anatomy

- inhaled irritants not only increase mucus production but also increase the size and number of **mucous glands** and **goblet cells** in airway epithelium
  - mucus produced is thicker and more tenacious than normal
  - sticky mucus coating makes it much more likely that bacteria, such as *H. influenzae* and *S. pneumoniae*, will become embedded in the airway secretions, there they reproduce rapidly
- **cilia** function is impaired, reducing mucus clearance further
  - lung's defense mechanisms are therefore compromised, increasing susceptibility to pulmonary infection and injury
- **bronchial wall** becomes inflamed and thickened from edema and accumulation of inflammatory cells
- initially chronic bronchitis affects only the larger bronchi, but eventually all airways are involved
- thick mucus and hypertrophied bronchial smooth muscle obstruct the airways and lead to closure, particularly during expiration, when the airways are narrowed
  - airways collapse early in expiration, trapping gas in the distal portions of the lung.
  - obstruction eventually leads to ventilation-perfusion mismatch, hypoventilation (increased PaCO<sub>2</sub>) and hypoxemia




# Lung emphysema


- abnormal permanent enlargement of gas-exchange airways = acini (i.e distally from terminal bronchioles) accompanied by **destruction of alveolar walls** and without obvious fibrosis
  - obstruction results from changes in lung tissues, rather than mucus production and inflammation, as in chronic bronchitis
- functional consequence:
  - major mechanism of airflow limitation is **loss of elastic recoil** leading to the **collapse of small airways** during expiration
  - expiration becomes difficult because loss of elastic recoil reduces the volume of air that can be expired passively,
  - combination of increased RV (and FRC) in the alveoli and diminished caliber of the bronchioles causes part of each inspiration to be trapped in the acinus
  - **hyperinflation** of alveoli causes large air spaces (bullae) and air spaces adjacent to pleura (blebs) to develop









# Healthy (left) vs. emphysematous lung (right)




# Emphysema types in COPD




- Centrilobular (centriacinar):
  - septal destruction occurs in the respiratory bronchioles and alveolar ducts, usually in the upper lobes of the lung
  - alveolar sac (alveoli distal to the respiratory bronchiole) remains intact
  - tends to occur **in smokers**
- Panacinar (panlobular):
  - involves the entire acinus with damage more randomly distributed and involving the lower lobes of the lung
  - tends to occur in patients with  **$\alpha$ 1-antitrypsin deficiency**

	Normal	Centriacinar (Centrilobular) Emphysema	Panacinar (Panlobular) Emphysema
ACINAR STRUCTURE			
LOBULAR PATTERN			

# Variable overlap in COPD









# Etiology of COPD - multifactorial


- smoking
  - cigarette smoke and air pollution, tip the normal balance of elastases (proteolytic enzymes) and antielastases (such as  $\alpha$ 1-antitrypsin) so that elastin is destroyed at an increased rate
  - $\uparrow$  number of neutrophil granulocytes in inflammed airways
    - source of elastases and proteases favoring emphysema development
  - tissue injury due to reactive oxygen and nitrogen species
    - healing with the participation of macrophages (source of matrix metalloproteinases)
  - hypertrophy of mucus glands and thus CHB
  - impairment of surfactant
- airway hyper-reactivity
- genetics (= variable consequences in two persons with equal „smoking“ history)
  - $\alpha$ 1-antitrypsin deficiency
    - $\alpha$ 1-antitrypsin inhibits neutrophil elastase which has the ability to destruct lung tissue
    - identified more than 75 alleles in the gene for  $\alpha$ 1-antitrypsin
  - other genes
    - pro-inflammatory cytokines, growth factors, protease/antiprotease balance, antioxidants etc.
- exposure to other air pollutants (dust, smoke, professional exposure, car traffic fumes, biomass burning etc.)
  - the most risky are small particles  $\leq 2.5 \mu\text{m}$
- recurrent lower airways and lung infections



# Effect of smoking




# Pulmonary vessels in COPD



- remodeling (i.e. wall thickening, lumen narrowing and increased resistance) present very early in the time course of COPD
  - endothelial dysfunction
    - due to oxidative stress
  - hyperplasia of tunica intima
    - cells (inflammatory cells and SMCs) as well as ECM
  - hypertrophy of tunica media
- gradually hypoxia and loss of capillaries (emphysema) contributes to remodeling as well
  - vasoconstriction
  - later pre-capillary form of secondary pulmonary hypertension
- cor pulmonale

# Clinical heterogeneity of COPD





- Type A – “pink puffer” - dominance of emphysema
  - patients with emphysema are able to maintain a higher alveolar minute ventilation (“puffers”) than those with chronic bronchitis
    - therefore they tend to have a higher  $\text{PaO}_2$  and lower  $\text{PaCO}_2$  and are indeed „pink“
  - a thin, tachypneic patient using accessory muscles and pursed lips to facilitate respiration
    - thorax is barrel-shaped due to hyperinflation
  - there is little cough and very little sputum production (in „pure“ emphysema)
- Type B – “blue bloater” – dominance of bronchitis
  - bronchitis patients are often „blue“ due to hypoxemia (and central cyanosis)/hypercapnia
  - they regularly exhibit right heart failure due to an increase in pulmonary artery pressure impairing right ventricular function
    - this leads to peripheral edema (“bloaters”)

**TABLE 22-2** Characteristics of Emphysema and Chronic Bronchitis

<b>Characteristic</b>	<b>Type A Pulmonary Emphysema ("Pink Puffers")</b>	<b>Type B Chronic Bronchitis ("Blue Bloaters")</b>
Smoking history	Usual	Usual
Clinical features		
Barrel chest (hyperinflation of the lungs)	Often dramatic	May be present
Weight loss	May be severe in advanced disease	Infrequent
Shortness of breath	May be absent early in disease	Predominant early symptom, insidious in onset, exertional
Decreased breath sounds	Characteristic	Variable
Wheezing	Usually absent	Variable
Rhonchi	Usually absent or minimal	Often prominent
Sputum	May be absent or may develop late in the course	Frequent early manifestation, frequent infections, abundant purulent sputum
Cyanosis	Often absent, even late in the disease when there is low PO <sub>2</sub>	Often dramatic
Blood gases	Relatively normal until late in the disease process	Hypercapnia may be present Hypoxemia may be present
Cor pulmonale	Only in advanced cases	Frequent Peripheral edema
Polycythemia	Only in advanced cases	Frequent
Prognosis	Slowly debilitating disease	Numerous life-threatening episodes due to acute exacerbations


# Bronchial asthma

- prevalence
  - 5-10% children
  - ~ 5% adults
- definition (GINA 2006)
  - a **chronic inflammatory disorder** of the airways in which many **cells** play a role
  - chronic inflammation causes an associated increase in **airway hyper-responsiveness** that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning
  - these episodes are usually associated with widespread but variable **airway obstruction** that is often reversible either spontaneously or with treatment
- types
  - allergic (extrinsic)
    - IgE-mediated bronchoconstriction
  - non-allergic (intrinsic)
    - IgE-independent = bronchial hyperreactivity
      - damage of epithelium
      - increased sensitivity to bronchoconstrictive agents




# IgE-mediated asthma

- due to the **atopy**
  - genetic predisposition to the alteration of immune response towards immunopathological reaction of type 1
    - ↑ formation of IgE
    - ↑ activity of CD4+Th2 cells (cytokines IL-4, 5, 6, 13)
    - altered Ag presentation by APC
    - different reactivity of target cells to mediators (histamine)
    - ↓ suppressor activity of T cells
    - ↑ number of mast cells
    - ↑ concentration of FcεR1 on their surface
  - IgE antibodies directed often against (aero)allergens
    - domestic (dust mites)
    - pollen
    - infection agents (bacteria, viruses)
    - others




# Polygenic nature of asthma







# Sensibilisation phase in atopic subjects



Proportions of asthmatic children sensitized to common allergens



# Pathogenesis of allergic asthma



Inhaled antigen is processed by dendritic cells and presented to Th2 CD4<sup>+</sup> T cells. B cells are stimulated to produce IgE, which binds to mast cells. Inhaled antigen binds to IgE, stimulating the mast cell to degranulate, which in turn leads to the release of mediators of the immediate response and the late response. Histamine and the leukotrienes produce bronchospasm and airway edema. Released chemotactic factors, along with factors from the Th2 CD4<sup>+</sup> T cells, facilitate eosinophil traffic from the bone marrow to the airway walls. These late responses are proposed to lead to excessive mucus production, airway wall inflammation, injury, and hyperresponsiveness. (GM-CSF—granulocyte-macrophage colony-stimulating factor; IFN- $\gamma$ —interferon gamma; IL—interleukin)

**Table 7.1 Characteristics of Th1 and Th2 cells**

	<b>Th1</b>	<b>Th2</b>
Cytokines	<ul style="list-style-type: none"> <li>• IL-2, IFN-<math>\gamma</math></li> <li>• IL-3, GMCSF</li> </ul>	<ul style="list-style-type: none"> <li>• IL-4, IL-5, IL-10, IL-13</li> <li>• IL-3, GMCSF</li> </ul>
Main receptors	<ul style="list-style-type: none"> <li>• IL-12R<math>\beta</math>, IL-18R</li> <li>• CXCR3, CCR5</li> </ul>	<ul style="list-style-type: none"> <li>• CCR4</li> </ul>
Effector functions	<ul style="list-style-type: none"> <li>• Macrophage activation</li> <li>• Complement-binding</li> <li>• Opsonization</li> <li>• Neutrophil activation</li> </ul>	<ul style="list-style-type: none"> <li>• Production of IgE</li> <li>• Production of neutralizing antibodies</li> <li>• Suppression of macrophage activation</li> <li>• Eosinophil activation, proliferation, maturation, recruitment</li> </ul>


GMCSF, granulocyte macrophage colony stimulating factor; IL, interleukin; IFN, interferon; IgE, immunoglobulin E.

**Table 7.2 Characteristics of regulatory T (Treg) cells**

<b>nTreg</b>	<b>aTreg: Th3</b>	<b>aTreg: Tr1</b>
<ul style="list-style-type: none"> <li>• T cell: T cell/APC contact</li> <li>• Generated in thymus</li> <li>• CD4+, CD25<sup>hi</sup>, CD45RO+, GITR+, CTLA4+, CD103+, Foxp3+</li> <li>• Protect against autoimmunity</li> <li>• 5–10% of CD4+ T cells</li> </ul>	<ul style="list-style-type: none"> <li>• Soluble/membrane TGF-<math>\beta</math></li> <li>• Generated in periphery (post-thymic)</li> <li>• Variable CD25 expression</li> <li>• Inhibit Th1 and Th2 responses</li> </ul>	<ul style="list-style-type: none"> <li>• Soluble IL-10</li> <li>• Generated in periphery (post-thymic)</li> <li>• Variable CD25 expression</li> <li>• Inhibit Th1 and Th2 responses</li> </ul>


Major characteristics of subsets of CD4+ Treg cell bases on cell-surface markers, immunosuppressive cytokine secretion and suppressive action. nTreg, natural Treg; aTreg, adaptive Treg; Th, T helper cell; Tr1, T-regulatory cell type 1; APC, antigen-presenting cell, TGF, transforming growth factor; IL, interleukin. (From Van Oosterhout AJ, Bloksma N (2005). Regulatory T-lymphocytes in asthma. *Eur Resp J*, 26:918–932.)

# Asthma – acute, late and chron. phase



- early phase (acute attack)
  - 15-30 min, mediators of mast cells (**histamine**)
    - immediate biological response but as well as chemotaxis of other cell types
  - ↑ secretion of mucus, edema of the bronchial wall
  - contraction of SMCs (bronchospasms)

# Asthma – acute, late and chron. phase




- late phase

- after 4-8 hrs
- mediators of neutrophils, **eosinophils**


- **leukotrienes** C, D and E, basic and cationic protein etc.

- inflammation (hyperemia, edema), hypersecretion of mucus, event. destruction of epithelium

# Mediators of mast cells and eosinophils




# Asthma – acute, late and chron. phase



- chronic phase
  - chronic inflammation + repair processes lead to irreversible structural (**remodelation**) and functional (**hyper-reactivity**) changes of airways constituting a vicious cycle
  - epithelium
    - ↓ cilia, desquamation
    - hypertrophy of mucus glands and hyperplasia of goblet cells
  - basal membrane
    - fibrotisation in subepithelialspace (collagen)
  - muscle layer
    - hypertrophy and hyperplasia of SMCs

**FIGURE 2-2. FACTORS LIMITING AIRFLOW IN ACUTE AND PERSISTENT ASTHMA**




Key: GM-CSF, granulocyte-macrophage colony-stimulating factor; IgE, immunoglobulin E; IL-3, interleukin 3 (and similar); TNF- $\alpha$ , tumor necrosis factor-alpha

Source: Adapted and reprinted from The Lancet, 368, Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults, 780–93. Copyright (2006), with permission from Elsevier.




# Mucus pathophysiology in asthma and COPD: similarities and differences



- In asthmatics, there is increased luminal mucus, a similar or increased ratio of mucin (MUC) 5B (low charge glycoform [lcgf]) to MUC5AC, small amounts of MUC2, epithelial 'fragility', marked goblet cell hyperplasia, submucosal gland hypertrophy (with normal mucous to serous cell ratio), 'tethering' of mucus to goblet cells, and plasma exudation. Airway inflammation involves T lymphocytes and eosinophils. In COPD, there is increased luminal mucus, an increased ratio of lcgf MUC5B to MUC5AC, small amounts of MUC2, goblet cell hyperplasia, submucosal gland hypertrophy (with an increased proportion of mucous to serous cells), and respiratory infection (possibly owing to reduced bacterial enzymatic 'shield' from reduced serous cell number). Pulmonary inflammation involves macrophages and neutrophils.

# The hyper-responsive airways in asthma respond to a wide-range of provoking factors




- parasympathetic nerve endings are close to the surface
  - damage leads to their exposure and increase of bronchoconstriction potential
- bronchomotoric tests
  - bronchodilations tests - reversibility of bronchial obstruction
    - salbutamol 200-400 ug
    - ipratropium 80 ug
  - bronchoconstriction test – bronchial hyperreactivity
    - histamine 1g in 100 ml of physiol. solution
    - metacholin

## Table 1.4 Stimuli that can provoke asthma symptoms


- Cold air
- Exercise
- Climate, including changes in temperature and humidity, e.g. fog
- Air pollution, both indoor and outdoor
- Fumes, including smoke, perfume, sprays
- Allergens, including house dust mite, cat, dog, moulds
- Medications, including
  - $\beta$ -blockers used for heart disease and high blood pressure
  - non-steroidal anti-inflammatory drugs such as aspirin used for pain relief or arthritis
- Emotion, including stress and loss (bereavement)
- Hormonal, such as premenstrual and during pregnancy
- Night-time and early morning
- Foods, including preservatives, such as tartrazine (orange colouring), monosodium glutamate (used in Chinese food), sulphites (included in some wines) and allergens such as peanuts, shellfish
- Workplace exposure to agents to which individuals become sensitized
- Alcohol
- Viral respiratory tract infections such as the common cold and influenza

# Aspirin-induced asthma (AIA)

- typical features:
  - first manifestation in 3<sup>rd</sup>-4<sup>th</sup> decade, more often women
  - whole year persisting cold
  - nasal polyps and blockage
- frequency:
  - ~10% of adult cases of asthma is in fact AIA
    - in general population 0.3-0.9%
- „aspirin trias“
  - sensitivity to ASA
  - asthma
  - persisting rhinosinusitis with nasal polyposis and eosinophilia



# Pathogenesis of virus-induced asthma



Inhaled virus infects epithelial cells and leads to apoptosis of some of them. The release of chemotactic factors promotes the recruitment of macrophages into the lung parenchyma, where they ingest the dead epithelium. An acute response consisting of bronchospasm occurs at this time. Similar to allergic asthma, the inhaled virus is processed by dendritic cells and presented to Th2 CD8+ T cells. These cells produce copious amounts of IFN- $\gamma$ . Perforin released from the T cells leads to apoptosis of infected cells. B cells produce IgG, which is capable of neutralizing the virus. These events are thought to be related to the chronic response, which consists of airway inflammation, goblet cell hyperplasia, and airway hyperresponsiveness. (IFN- $\gamma$ —interferon gamma; IL—interleukin; CCL—chemokine ligand)

# Asthma – clinical manifestation

- During full remission
  - individuals are asymptomatic and pulmonary function tests are normal
- During partial remission
  - no clinical symptoms but pulmonary function tests are abnormal
- During attacks
  - dyspnea and ↑ respiratory effort, wheezing, non-productive coughing, tachycardia and tachypnea
- Diagnosis
  - spirometry
    - ↓ expiratory flow rate, forced expiratory volume (FEV<sub>1</sub>), and forced vital capacity (FVC)
    - ↑ FRC and total lung capacity (TLC)
  - blood gas analysis shows respiratory insufficiency
    - initially partial (i.e. hypoxemia with respiratory alkalosis)
    - later global (i.e. hypercapnia and respiratory acidosis)

